MX375745B - Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada. - Google Patents

Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada.

Info

Publication number
MX375745B
MX375745B MX2016015516A MX2016015516A MX375745B MX 375745 B MX375745 B MX 375745B MX 2016015516 A MX2016015516 A MX 2016015516A MX 2016015516 A MX2016015516 A MX 2016015516A MX 375745 B MX375745 B MX 375745B
Authority
MX
Mexico
Prior art keywords
long
acting
diabetes
conjugate
composition
Prior art date
Application number
MX2016015516A
Other languages
English (en)
Other versions
MX2016015516A (es
Inventor
Kim Dae Jin
Choi In Young
Kuk Kim Jung
Kwon Se Chang
Jung Sung Youb
Heo Yong Ho
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of MX2016015516A publication Critical patent/MX2016015516A/es
Publication of MX375745B publication Critical patent/MX375745B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición para la prevención o tratamiento de la diabetes que incluye un conjugado de insulina de acción prologada y un conjugado de péptido insulinotrópico de acción prolongada, y un método para tratar la diabetes. Más específicamente, la administración de la combinación del conjugado de análogo de acción prolongada y el conjugado de péptido insulinotrópico de acción prolongada, inhibe el aumento de peso debido a la administración de insulina, y los vómitos y náuseas debidos a la administración del péptido insulinotrópico, y también reduce la dosis requerida de insulina, mejorando notablemente de esta forma la observancia del fármaco. Además, la presente invención se refiere a la administración de una composición farmacéutica para reducir efectos secundarios de las células beta pancreáticas en pacientes diabéticos, que incluye un conjugado de análogo de insulina de acción prolongada y un conjugado de análogo de péptido insulinotrópico de acción prolongada, y a un método para reducir los efectos secundarios de células beta pancreáticas en pacientes diabéticos, que incluye la etapa de administrar la composición. Específicamente, la presente invención se caracteriza por la reducción de efectos secundarios tales como la anomalía en la función de células beta pancreáticas asociada con el desarrollo de diabetes, reducción de la masa de células beta pancreáticas, lipotoxicidad o glucotoxicidad.
MX2016015516A 2014-05-29 2015-05-29 Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada. MX375745B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140065072 2014-05-29
PCT/KR2015/005424 WO2015183038A1 (ko) 2014-05-29 2015-05-29 지속형 인슐린 아날로그 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물

Publications (2)

Publication Number Publication Date
MX2016015516A MX2016015516A (es) 2017-03-29
MX375745B true MX375745B (es) 2025-03-06

Family

ID=54699297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015516A MX375745B (es) 2014-05-29 2015-05-29 Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada.

Country Status (24)

Country Link
US (1) US10159715B2 (es)
EP (1) EP3156066B1 (es)
JP (2) JP7014515B2 (es)
KR (2) KR20150138101A (es)
CN (2) CN119454911A (es)
AR (1) AR100639A1 (es)
AU (1) AU2015268183B2 (es)
CL (1) CL2016003075A1 (es)
CR (1) CR20160582A (es)
DK (1) DK3156066T5 (es)
DO (1) DOP2016000302A (es)
EA (1) EA038431B1 (es)
EC (1) ECSP16096962A (es)
ES (1) ES2949553T3 (es)
IL (1) IL249246B (es)
MX (1) MX375745B (es)
MY (1) MY181539A (es)
PE (1) PE20170195A1 (es)
PH (2) PH12016502391B1 (es)
SG (1) SG11201609564TA (es)
TN (1) TN2016000500A1 (es)
TW (3) TW202140065A (es)
UA (1) UA125847C2 (es)
WO (1) WO2015183038A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10253082B2 (en) 2014-01-20 2019-04-09 Hanmi Pharm. Co., Ltd Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
TN2017000555A1 (en) 2015-06-30 2019-04-12 Hanmi Pharm Ind Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
PH12018501409B1 (en) 2015-12-31 2023-03-10 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
JP7208020B2 (ja) * 2016-06-29 2023-01-18 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途
US11396534B2 (en) 2016-09-23 2022-07-26 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
WO2018143729A1 (ko) * 2017-02-03 2018-08-09 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
WO2018174668A2 (ko) * 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
US11459368B2 (en) 2017-07-14 2022-10-04 Livactus, Inc. Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance
WO2019066603A1 (ko) * 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
WO2019103875A2 (en) * 2017-11-21 2019-05-31 Eli Lilly And Company Methods of using and compositions containing dulaglutide
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR102646845B1 (ko) * 2018-08-08 2024-03-14 주식회사 대웅제약 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
SG11202106168VA (en) * 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
KR102193211B1 (ko) * 2019-11-27 2020-12-18 (주)디앤디파마텍 비오틴 모이어티가 결합된 폴리펩티드 및 이를 포함하는 경구 투여용 약학적 조성물
BR112022011291A2 (pt) * 2019-12-10 2022-09-06 Sanofi Sa Método para formar um conjugado de uma sulfonamida e um polipeptídeo
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
CN115803015A (zh) * 2020-05-22 2023-03-14 韩美药品株式会社 胰高血糖素衍生物的长效缀合物的液体制剂
CN114075275A (zh) * 2020-08-17 2022-02-22 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114478744A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效glp-1拮抗剂
CN113801242B (zh) * 2021-09-17 2024-05-17 南通大学 一种长效胰岛素及其体外细胞生产加工方法
CN113929762B (zh) * 2021-12-16 2022-04-26 清华大学 3-羟基丁酰化和/或3-羟基戊酰化修饰胰岛素及其应用
WO2025135700A1 (ko) * 2023-12-21 2025-06-26 포항공과대학교 산학협력단 지속형 인슐린 유전자 컨스트럭트 및 이의 용도

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5422339A (en) 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
JP2005508360A (ja) * 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１およびインスリンの二相混合物
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060217290A1 (en) 2003-04-29 2006-09-28 Kohn Wayne D Insulin analogs having protracted time action
SI1648933T1 (sl) 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
EP2404934A1 (en) * 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP5688969B2 (ja) * 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
EP2017288A1 (en) 2007-07-16 2009-01-21 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
ES2612736T3 (es) * 2007-11-16 2017-05-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
NZ586589A (en) 2008-01-09 2012-04-27 Sanofi Aventis Deutschland Novel insulin analogues having an extremely delayed time-action profile
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
TW201100104A (en) * 2009-03-27 2011-01-01 Glaxo Group Ltd Drug fusions and conjugates
US20120184488A1 (en) 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
PT2554183T (pt) * 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
KR101058209B1 (ko) 2009-12-30 2011-08-22 전자부품연구원 Ｏｆｄｍ 방식의 디지털 방송 시스템의 빠른 동기 방법
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
KR101330868B1 (ko) 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
MA34913B1 (fr) 2011-01-20 2014-02-01 Zealand Pharma As Combinaison d'analogues du glucagon acylé à des analogues d'insuline
CN103635602B (zh) 2011-03-02 2016-08-31 欧瑞康表面解决方案股份公司，普费菲孔 用于在润滑条件下通过摩擦应用改进磨损和摩擦性能的用含金属碳层涂布的滑动组件
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
US9341445B2 (en) 2011-05-03 2016-05-17 Teijin Aramid Bv Antiballistic panel with first and second laminates having fibers of different tensile modulus
EP2714070B1 (en) 2011-06-02 2024-03-20 OPKO Biologics Ltd. Long-acting glp-1/glucagon receptor agonists
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
HRP20181591T1 (hr) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
CN103596584B (zh) * 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
AU2012270366C1 (en) 2011-06-17 2017-07-13 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US9165768B2 (en) 2011-12-16 2015-10-20 Lg Innotek Co., Ltd. Method for deposition of silicon carbide and silicon carbide epitaxial wafer
US20150299286A1 (en) 2012-01-20 2015-10-22 Case Western Reserve University Glutamic acid-stabilized insulin analogues
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
NZ739063A (en) 2012-11-06 2019-11-29 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
PE20151409A1 (es) 2013-02-26 2015-10-07 Hanmi Pharm Ind Co Ltd Analogo de insulina novedoso y su uso
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR101676542B1 (ko) 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도

Also Published As

Publication number Publication date
PH12021551747A1 (en) 2023-03-13
EP3156066B1 (en) 2023-04-26
TW202235101A (zh) 2022-09-16
DOP2016000302A (es) 2016-12-15
MY181539A (en) 2020-12-26
ECSP16096962A (es) 2018-04-30
CN106559984A (zh) 2017-04-05
EP3156066A4 (en) 2017-12-13
CL2016003075A1 (es) 2017-05-26
KR20150138101A (ko) 2015-12-09
NZ726959A (en) 2023-09-29
CN119454911A (zh) 2025-02-18
TWI784914B (zh) 2022-11-21
TW201607553A (zh) 2016-03-01
IL249246A0 (en) 2017-02-28
AU2015268183A1 (en) 2016-12-22
ES2949553T3 (es) 2023-09-29
KR102449145B1 (ko) 2022-09-30
AU2015268183B2 (en) 2020-09-17
PH12016502391B1 (en) 2023-01-11
BR112016027469A2 (pt) 2017-10-17
EP3156066A1 (en) 2017-04-19
SG11201609564TA (en) 2016-12-29
CR20160582A (es) 2017-03-15
UA125847C2 (uk) 2022-06-22
DK3156066T5 (da) 2024-06-10
WO2015183038A1 (ko) 2015-12-03
MX2016015516A (es) 2017-03-29
TW202140065A (zh) 2021-11-01
KR20220061057A (ko) 2022-05-12
JP2020143155A (ja) 2020-09-10
PE20170195A1 (es) 2017-03-19
JP2017521377A (ja) 2017-08-03
EA201692159A1 (ru) 2017-06-30
CA2950266A1 (en) 2015-12-03
TN2016000500A1 (en) 2018-04-04
DK3156066T3 (da) 2023-07-24
JP7014515B2 (ja) 2022-02-01
AR100639A1 (es) 2016-10-19
PH12016502391A1 (en) 2017-02-20
US20170143802A1 (en) 2017-05-25
IL249246B (en) 2020-01-30
EA038431B1 (ru) 2021-08-27
US10159715B2 (en) 2018-12-25

Similar Documents

Publication Publication Date Title
MX375745B (es) Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MY175421A (en) Compositiion for treating diabetes mellitus comprising insulin and a glp - 1/glucagon dual agonist
GB2507884A (en) Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
MX2019007088A (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
MX2014013091A (es) Composicion farmaceutica.
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
CL2014001705A1 (es) Compuestos derivados de aza adamantano, inhibidores de 11beta-hsd-1; composicion farmaceutica; metodo para prevencion o tratamiento; y uso para prevenir o tratar el sindrome metabolico, diabetes tipo 2 como consecuencia de obesidad, resisitencia a insulina, dislipidemia, neuropatia, isquemia e infarto, entre otras enfermedades.
EA201491831A1 (ru) Содержащие прасугрель стабильные фармацевтические композиции с немедленным высвобождением для перорального введения
MX342020B (es) Apolipoproteina a-iv como un peptido antidiabetico.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2014010989A (es) Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos.
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
MX2018007377A (es) Composicion de acido hialuronico para inyecciones en el pene.
RU2012123182A (ru) Способ коррекции психического состояния пациентов и антиоксидантого статуса при органическом расстройстве личности
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
RU2014147357A (ru) Применение l-карнитина в качестве средства снижения риска развития фатальной аритмии
IN2013MU01156A (es)
UA89638U (ru) Способ лечения больных пожилого возраста с синдромом сосудистых умеренных когнитивных нарушений
IN2013MU01157A (es)
EA201892708A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе

Legal Events

Date Code Title Description
FG Grant or registration